{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:00:47Z","timestamp":1784127647253,"version":"3.55.0"},"reference-count":69,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Anim Models and Exp Med"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rituximab is a chimeric monoclonal antibody that binds to<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>20 antigen of B\u2010cells. It depletes the level of mature B\u2010cells by various mechanisms such as mediation of antibody\u2010dependent cellular cytotoxicity, complement\u2010dependent cytotoxicity, and B\u2010cell apoptosis. Rituximab is a<jats:styled-content style=\"fixed-case\">USFDA<\/jats:styled-content>approved drug for clinical use in non\u2010Hodgkin's B\u2010cell lymphoma (<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>), rheumatoid arthritis, chronic lymphocytic leukemia (<jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>), granulomatosis with polyangiitis and pemphigus vulgaris. It is also known for its \u201coff label\u201d use in renal disease and renal transplant worldwide. However, the exact mechanisms by which it exerts its effect in the aforementioned condition remain unclear but may be related to its long\u2010term effects on plasma cell development and the impact on B\u2010cell modulation of T cell responses. This review discusses the current use of rituximab in renal disease and renal transplantation, and its potential role in novel therapeutic protocols.<\/jats:p>","DOI":"10.1002\/ame2.12064","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T20:43:44Z","timestamp":1553633024000},"page":"76-82","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Rituximab in kidney disease and transplant"],"prefix":"10.1002","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-1767","authenticated-orcid":false,"given":"Kajal","family":"Chauhan","sequence":"first","affiliation":[{"name":"Medical Services Torrent Pharmaceuticals Ahmedabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita A.","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology L. M. College of Pharmacy Ahmedabad Gujarat India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddstr.2009.10.001"},{"key":"e_1_2_11_4_1","first-page":"76","article-title":"Role of rituximab in first\u2010line treatment of chronic lymphocytic leukemia","volume":"7","author":"Bryan J","year":"2011","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_11_5_1","unstructured":"FDA Approves Genentech's Rituxan (Rituximab) for Pemphigus Vulgaris. June 7 2018.https:\/\/www.gene.com\/media\/press-releases\/14727\/2018-06-07\/fda-approves-genentechs-rituxan-rituxima. Accessed January 9 2019."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01288.x"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1739"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-015-0016-9"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312471574"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05231008"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34331"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-3928-1"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2005.00334.x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00234"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/096120339500400206"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2005.05.006"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp336"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2016-000182"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0270-9295(03)00049-4"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00710805"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810457"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002628"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11042-7"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfw091"},{"key":"e_1_2_11_26_1","first-page":"621","article-title":"Association between hepatitis C virus and mixed cryoglobulinemia","volume":"19","author":"Ferri C","year":"1991","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-101717"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34322"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00778.x"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001160"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002231"},{"issue":"643","key":"e_1_2_11_32_1","first-page":"e9","article-title":"ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis","volume":"120","author":"Finkielman JD","year":"2007","journal-title":"Am J Med"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy075"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-196603000-00003"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0193"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-0848"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0631-0"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0964-6"},{"key":"e_1_2_11_41_1","first-page":"203","article-title":"Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura \u2013 haemolytic uraemic syndrome","volume":"8","author":"Caramazza D","year":"2010","journal-title":"Blood Transfus"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000078622.43689.D4"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.09.002"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002197"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.07.046"},{"key":"e_1_2_11_46_1","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.3760\/cma.j.issn.0366-6999.2009.22.015","article-title":"Protein A immunoadsorption combined with rituximab in highly sensitized kidney transplant recipients","volume":"122","author":"Yin H","year":"2009","journal-title":"Chin Med J (Engl)"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.261"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.4103\/0971-4065.179305"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02411.x"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2017.01.002"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2011.12.006"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-010-0132-1"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2001.003002070.x"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2006.00284.x"},{"key":"e_1_2_11_55_1","first-page":"196","article-title":"Treatment of post\u2010transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m\u2010TOR inhibitor","volume":"47","author":"Nieto\u2010Rios JF","year":"2016","journal-title":"Colomb Med"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000071511.35221.B3"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05080610"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.5414\/CN107912"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012020181"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1159\/000327611"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00507.x"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000296031.41424.f8"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20206"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr237"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v5.i4.329"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.4103\/0971-4065.159557"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2016.01.027"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12249"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12408"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2016.06.048"}],"container-title":["Animal Models and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ame2.12064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ame2.12064","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ame2.12064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T05:14:19Z","timestamp":1721106859000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ame2.12064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1002\/ame2.12064"],"URL":"https:\/\/doi.org\/10.1002\/ame2.12064","archive":["Portico"],"relation":{},"ISSN":["2576-2095","2576-2095"],"issn-type":[{"value":"2576-2095","type":"print"},{"value":"2576-2095","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,26]]},"assertion":[{"value":"2019-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}